Abbott Diagnostics restructuring
This article was originally published in The Gray Sheet
Executive Summary
Business unit will lay off about 1,100 employees worldwide and reorganize into four operations focusing on immunochemistry, hematology, molecular and blood glucose monitoring. Worldwide diagnostics sales of $733 mil. in the third quarter were basically flat (up 0.8%), including a 9% decline in U.S. diagnostics revenues to $288 mil. Abbott notes it has hired Bio-Reg and AccuReg as new third-party consultants to assist in resolving its 1999 FDA consent decree. The diagnostics restructuring is part of a larger plan to increase bottom-line accountability and save $80-100 mil. annually by 2005, Abbott notes. Company-wide, 2,000 positions will be cut, or 3% of Abbott's workforce, and ten facilities shuttered. A fourth-quarter charge of $100-125 mil. will be recorded...
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.